human glp-1 (Ser8)-GLP-1 (7-36), amide, GLP-1 and the Degenerating Brain:

These approaches address the root cause rather than masking symptoms

From the phase 3 trials at the 9 mg and 12 mg doses: Nausea: 38.1% (9 mg) to 43.2% (12 mg) versus 10.7% with placebo Diarrhea: 34.7% (9 mg) to 33.1% (12 mg) versus 13.4% with placebo Constipation: 21.8% (9 mg) to 25.0% (12 mg) versus 8.7% with placebo Vomiting: 20.4% (9 mg) to 20.9% (12 mg) Compare those numbers to Mounjaro and the difference is clear

Your own fat tissue is making them for free, while you sleep

The SkinCeuticals team, which focuses heavily on the crossover between medical aesthetics and complementary topical products, saw the growing opportunity to tap into the GLP-1 market through skin care solutions